Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...
Is Christianity just a copycat religion? Many critics answer, “Yes,” and argue that much of the Old Testament is nothing more ...
Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback